4875 Stock Overview A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
MediciNova, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for MediciNova Historical stock prices Current Share Price US$286.00 52 Week High US$354.00 52 Week Low US$155.00 Beta 0.82 1 Month Change -10.63% 3 Month Change -10.06% 1 Year Change 40.20% 3 Year Change 3.25% 5 Year Change -57.38% Change since IPO -27.23%
Recent News & Updates
MediciNova, Inc. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 25
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10 See more updates
MediciNova, Inc. to Report Fiscal Year 2024 Results on Feb 14, 2025 Jan 25
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer Jun 06
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024 Jun 05
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 15
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 08
MediciNova, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 12
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan Mar 27
Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology Mar 12
MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024 Jan 22
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China Jan 17
MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology Dec 22
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe Dec 07
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada Oct 11
MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023 Oct 08
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology Aug 19 MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe
Less than half of directors are independent Aug 12
MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting Jun 30
MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID Feb 09
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder Jan 31
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma Jan 13
MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada Jan 12
MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil Jan 10
MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers Jan 06
MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation Dec 08
Independent Director recently sold JP¥95k worth of stock Nov 22
MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022 Oct 06
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada Sep 14
First half 2022 earnings released Aug 13
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea Jul 28
MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia Jul 27
MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022 Jul 24
MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) Jul 22
MediciNova, Inc. Announces Executive Changes Jun 22 MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Jun 09
Price target decreased to JP¥1,100 Apr 27
MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022 Apr 24
MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research Apr 21
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Apr 13
MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia Apr 12
MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research Apr 08
MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs Feb 24
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada Feb 01
MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe Jan 28
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS Dec 15
MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND Dec 11
Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology Nov 24
MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND Aug 31
Chief Financial Officer Edward Stepanow has left the company Aug 04 MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index
MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal Jun 22
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury Jun 08
Forecast breakeven pushed back to 2024 May 15
MediciNova, Inc. a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe May 06
Independent Director recently sold JP¥1.9m worth of stock Mar 17
New 90-day high: JP¥798 Mar 11
MediciNova, Inc. Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-Induced Lung Injury Mar 10
MediciNova, Inc. Announces Update on SARS-CoV-2 Vaccine for Covid-19 Mar 05
New 90-day high: JP¥670 Feb 05
MediciNova, Inc. announced that it has received $19.999999 million in funding from 3D Investment Partners Pte. Ltd Feb 02
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (Ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Japan Jan 20
MediciNova, Inc. announced that it expects to receive $19.999999 million in funding from 3D Investment Partners Pte. Ltd Jan 13
Medicinova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS Dec 30
New 90-day low: JP¥456 Dec 28
MediciNova, Inc. Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 in Progressive MS Published in Multiple Sclerosis Journal Nov 26
New 90-day high: JP¥635 Nov 16
MediciNova, Inc. Announces Positive Findings on MN-001 in Acute Liver Injury Model Oct 14
New 90-day low: JP¥538 Sep 30
MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology Sep 25
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies against SARS-CoV-2 in Mice using BC-PIV Vector Technology Sep 24
Independent Director recently sold JP¥610k worth of stock Sep 20
Independent Director recently sold JP¥609.9k worth of stock Sep 17
New 90-day low - JP¥558 Sep 04
New 90-day high - JP¥858 Jul 28 Shareholder Returns 4875 JP Biotechs JP Market 7D -2.4% 0.3% -1.6% 1Y 40.2% 19.4% 5.8%
See full shareholder returns
Return vs Market: 4875 exceeded the JP Market which returned 5.8% over the past year.
Price Volatility Is 4875's price volatile compared to industry and market? 4875 volatility 4875 Average Weekly Movement 12.1% Biotechs Industry Average Movement 8.8% Market Average Movement 3.5% 10% most volatile stocks in JP Market 7.5% 10% least volatile stocks in JP Market 1.8%
Stable Share Price: 4875's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4875's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company’s product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers.
Show more MediciNova, Inc. Fundamentals Summary How do MediciNova's earnings and revenue compare to its market cap? 4875 fundamental statistics Market cap JP¥13.95b Earnings (TTM ) -JP¥1.57b Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4875 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$10.29m Earnings -US$10.29m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) -0.21 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 0%
How did 4875 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/10 20:35 End of Day Share Price 2025/02/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources MediciNova, Inc. is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Buck B. Riley Securities, Inc. Yen Ting Chen Credit Suisse Jason Kolbert D. Boral Capital LLC.
Show 7 more analysts 
